Orexigen Therapeutics — Corporate Update (March 2017)
56 slides from Orexigen Therapeutics's corporate update, Mar 8, 2017
Slide 1: Business Update For Investors
Business Update For Investors March 7, 2017 We help improve the health and lives of patients struggling to lose weight Exhibit 99.1
Slide 2: Forward-looking statements
This presentation contains forward-looking statements about Orexigen Therapeutics, Inc. and Contrave® and Mysimba®. Words such as “believes,”“anticipates,” “plans,” “expects,” “indicates,” “will,” “should,” “intends,” “potential,” “suggests,” “assuming,” “designed” and similar expressions are intend
Slide 3: Indication and boxed warning
Indicated for use as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid conditio
Slide 4: Obesity: An Unprecedented Health Crisis and a Very Large Market Opportunity
Obesity: An Unprecedented Health Crisis and a Very Large Market Opportunity… but Progress Has Been Elusive Sources: Patients with BMI of 30+, BMI 27-29 with co-morbidities. Orexigen Segmentation Research based on CDC data. National Center for Health Statistics: Obesity/Overweight. 2015. https://www.
Slide 5: Review of 2016 and Preview of 2017
Review of 2016 and Preview of 2017 Strategy for Orexigen Re-Launch of Contrave Early Results for Orexigen Commercialization of Contrave Global Partnering Progress Post-Marketing Studies Early Program Development Summary
Slide 6: 2016 Review: Acquired Full Control of Contrave
Q1 2016 Acquired US rights to Contrave from Takeda Raised $165M to commercialize Contrave in the US Commercialization agreement for Central/Eastern Europe 2017 Q1 Q2 Q3 Q4 Q2 2016 Built commercial infrastructure for Orexigen US Contrave approved and launched in South Korea Favorable Markman hearing
Slide 7: 2017 A Value Inflection Year
Drive Contrave growth in the US Implement an innovative, patient-focused education and awareness campaign Integrate physician programs with patient programs to drive higher quality discussions on Rx-assisted weight loss Realize significant OUS opportunity Support successful launches and approvals in
Slide 8: Review of 2016 and Preview of 2017
Review of 2016 and Preview of 2017 Strategy for Orexigen Re-Launch of Contrave Early Results for Orexigen Commercialization of Contrave Global Partnering Progress Post-Marketing Studies Early Program Development Summary
Slide 9: Physician Awareness Achieved, Contrave Became #1 Prescribed Weight-Loss Brand
A High Degree of Physician Awareness Was Achieved, and Contrave Rapidly Became the #1 Prescribed Weight-Loss Brand1, but Flattening Sales Required a New Approach Source: QuintilesIMS, NPA Market Dynamics data for the period November 2015 – November 2016 Since August transition, Orexigen is executing
Slide 10: HCP Awareness Reached a Threshold
HCP Awareness Reached a Threshold Where Patients Who Request Contrave Would Likely Encounter a Receptive HCP Source: Feb 2016, Qualtrics internet survey, HCP distribution: 51% PCP, 18% ENDO, 18% MLP, 13% OBGYN Q100. We would like you to think about prescription products to treat obesity. Please type
Slide 11: Patients Are Receptive to Rx-Aided Weight Loss, but Awareness Is Low
Patients Are Receptive to Rx-Aided Weight Loss, but Awareness Is Low Sources: 1. Orexigen Pre-DTC Baseline study, n=1,000 2. Orexigen Pre-DTC Baseline study, n=1,000, aided and unaided awareness Only 9% of target patients struggling to lose weight are aware of Contrave2 45% 45% of motivated patient
Slide 12: Activating Patients Is a Critical Step
Activating Patients Is a Critical Step Ready To Be Taken 60% HCPs prescribe Contrave 60% of the time a patient requests it1 2% Of total Contrave prescriptions, only 2% are driven by patient requests2 Sales force equips the HCP to take this action DTC equips the patient to take this action Sources: 1
Slide 13: Increasing Patient-Physician Engagement About Contrave
Increasing and Enhancing Patient-Physician Engagement About Contrave-Assisted Weight-Loss HCP Activation Campaign Over 1.1M details delivered ~74,000 unique doctors have prescribed Contrave HCP speaker programs have reached 30,000+ attendees Samples program Focus on core group of 20,000 top weight-l
Slide 14: Re-Launch: Grow Sales with Lower Sales and Marketing Spend
Orexigen Re-Launch of Contrave: Aim to Significantly Grow Sales with a Lower Overall Sales and Marketing Spend by Changing the Approach $187M $127M $80-90M Reps: $112M Reps: $77M Reps HCP Mktg. HCP Mktg.: $67M HCP Mktg.: $42M Patient Mktg. Note: Year 1 and 2 base sales expense assume $125 per PDE wi
Slide 15: Focus on Biological Mechanisms That Make Losing Weight Challenging
A Key Part of the Orexigen Re-Launch Is to Focus on Biological Mechanisms that Make Losing Weight Challenging POMC Endorphin Hypothalamus Mesolimbic Reward System Orexigen has been focused on science in the hypothalamus and mesolimbic reward system since 2001
Slide 16: Mechanism of Action for Contrave
A Key Part of the Orexigen Re-Launch Is to Focus on the Mechanism of Action for Contrave POMC Endorphin Hypothalamus Mesolimbic Reward System Bupropion activates POMC which suppresses appetite Naltrexone blocks the Endorphin feedback loop Contrave is believed to work on two areas of the brain to red
Slide 17: New Messaging: Believed to Work on Two Areas of the Brain
Since Launch of New Messaging, “Believed to Work on Two Areas of the Brain” Is a Key Message for Both HCPs and Patients Source: Contrave® intent to prescribe survey 2016 n=419; Monitor Deloitte analysis; Ad quantitative test (prelim) n=150 Nov. 2016 Messages that drive intent to prescribe Contrave f
Slide 18: Majority of HCPs Associate Two Areas of the Brain with Contrave
Majority of HCPs Associate “Two Areas of the Brain” with Contrave Brand recalled with “the weight loss drug that is believed to work on two areas of my brain” Source: HCP Pulse Survey – Patient Requests, n=61 Nov. 2016 Q3) If a patient asks about “the weight loss drug that works in two areas of my b
Slide 19: Broadcast DTC Ad Activates Patients to Talk to a Doctor
Broadcast DTC Ad Provides Helpful and Compelling Information Which Activates Patients to Talk About Contrave with a Doctor Ad Messages that Establish Efficacy: “Across three long term studies, Contrave patients lost approximately 2–4X more weight than diet and exercise alone” “…help adults who are o
Slide 20: Contrave Ad Tested Above DTC Norms
Contrave Ad Tested Significantly Above DTC Norms in Five of the Most-Important DTC Categories Brand Appeal Brand Differentiation New Information Ad Distinctiveness Call to Action Category Contrave DTC Norm 4.01 4.01 3.55 3.05 3.69 3.81 3.85 3.03 2.82 3.16 Source: Ad quantitative test (prelim) n=150
Slide 21: Campaign Appearing in Key Primetime Television and Print Outlets
Campaign Is Appearing in Key Primetime Television and Print Outlets
Slide 22: 360° Patient-Centric Multimedia Campaign
360° Patient-Centric Multimedia Campaign Print HCP Office Social Media Website Digital Banners And Video In-office Brochure TV Find a Doctor Doctor Discussion Guide Telemedicine Doctor Discussion Guide
Slide 23: New Contrave Website
New Contrave Website Plays a Pivotal Role in Enabling Higher-Quality Patient-Physician Conversations About Contrave-Assisted Weight Loss Website includes full prescribing information, including important safety information
Slide 24: Close Monitoring of Patient-Centric and HCP Campaigns
Close Monitoring of Both the Patient-Centric and HCP Campaigns Allows for Rapid Adjustment and Performance Optimization DTC Campaign Total Sessions Bounce Rate Pages Per Session Time Spent on Site Top pages Traffic sources Unique Visitors Avg. Session Duration Impressions Find a Doctor Clicks Saving
Slide 25: Review of 2016 and Preview of 2017
Review of 2016 and Preview of 2017 Strategy for Orexigen Re-Launch of Contrave Early Results for Orexigen Commercialization of Contrave Global Partnering Progress Post-Marketing Studies Early Program Development Summary
Slide 26: Patient Campaign Driving Increase in Patient Interest and Action
26 Patient Activation Campaign Is Driving a Significant Increase in Patient Interest and Action Website Visits Find a Doctor Searches Dr. Discussion Guide Printouts Patient Campaign Patient Campaign Patient Campaign Pharmacy Savings Card Enrollments Patient Campaign Source: Google Analytics; McKesso
Slide 27: Contrave Reached New High for Weekly TRx Volume
Contrave Has Reached a New High for Weekly TRx Volume Contrave Belviq Qsymia Saxenda Source: QuintilesIMS NPA Weekly, Week Ending 02/24/17 Orexigen Transition Patient Campaign Previous High
Slide 28: Sharp Increase in Total Rx Share Since Patient Campaign
Sharp Increase in Total Rx Share Since Launch of Patient Campaign (Overall Market Including Generics) Contrave Belviq Qsymia Saxenda Source: QuintilesIMS NPA Weekly, Week Ending 02/24/17 Orexigen Transition Patient Campaign Previous High
Slide 29: New High for Total Rx Share of Branded Market
Contrave Has Reached a New High for Total Rx Share of the Branded Market Contrave Belviq Saxenda Source: QuintilesIMS NPA Weekly, Week Ending 02/24/17 Orexigen Transition Patient Campaign Qsymia Previous High
Slide 30: New to Brand Volume Significantly Above Previous High
New to Brand (NBRx) Volume Significantly Above Previous High NBRx Volume Source: QuintilesIMS Market Dynamics, Week Ending 02/24/17 Orexigen Transition Patient Campaign Previous High
Slide 31: Contrave Share of Total Market New Therapy Starts
Contrave Share of the Total Market New Therapy Starts Has Grown Significantly Share of Overall Market - phentermine Share of Overall Market - Contrave Contrave Phentermine Source: QuintilesIMS Market Dynamics, Week Ending 02/24/17 Orexigen Transition Patient Campaign Previous High Note: : ‘New Thera
Slide 32: Contrave Share of New Therapy Starts (Branded Market)
Contrave Share of New Therapy Starts (Branded Market) Has Grown Significantly Contrave Previous High Orexigen Transition Patient Campaign Belviq Qsymia Saxenda Share of Branded Market Source: QuintilesIMS Market Dynamics, Week Ending 02/24/17 Note: : ‘New Therapy Starts’ are defined as a new Rx for
Slide 33: Switches to Contrave Increased Relative to Generic Agents
Switches to Contrave Have Increased Relative to Generic Agents Since the Launch of the Patient Campaign (Overall Market) Share of Overall Market (Switches) Orexigen Transition Patient Campaign Source: QuintilesIMS Market Dynamics, Week Ending 02/24/17 Note: Switch data includes add-ons 5.3% 5.7% 6.4
Slide 34: Number of First-Time Prescribers Is Growing
The Number of First-Time Prescribers Is Growing Since the Launch of the Patient Campaign Patient Campaign New Prescribers of Contrave Source: IMS Xponent Weekly Data (Week ending 02/10/17)
Slide 35: Telemedicine with Get Contrave Now
Orexigen Offers Patients Telemedicine with “Get Contrave Now” Website includes full prescribing information, including important safety information
Slide 36: Why Telemedicine for Contrave?
Many patients are struggling with weight loss: Prefer a telemedicine option because of convenience and anonymity Are already part of online weight loss communities for diet and exercise (and can be accessed efficiently) Straightforward diagnosis and assessment: Indicated: BMI, risk factors Exclusion
Slide 37: Americans Are Ready for Telemedicine
Americans Are Ready for Telemedicine Telehealth is a significant and rapidly growing component of health care in the US 1 ~200 telehealth networks, with 3,500 service sites 47 states permit HCPs to write Rx’s after talking to patients on laptop or phone 30 states and the DC require private insurers
Slide 38: Employers Drive Adoption of Telemedicine Services
Employers Are a Key Lever in Driving the Adoption of Telemedicine Services by Offering and Reimbursing Source: Mercer’s National Survey of Employer-Sponsored Health Plans; n=2500; “Employer-reimbursed” is defined as employers with telemedicine offering that share the cost of the visit via co-pay aft
Slide 39: Our Telemedicine Approach
Our Telemedicine Approach Here’s how it works: Get Contrave Now Via Contrave.com Medical questionnaire creates electronic health record Home delivery Online consultation with board-certified, licensed physicians For appropriate patients, valid electronic prescription sent to pharmacy 1 2 3 4 5 Orexi
Slide 40: Telemedicine Focuses on Non-Scheduled Rx Products
Telemedicine Focuses on Prescribing Non-Scheduled/Non-Controlled Rx Products Note: 21 USC Section 831, 2008; Share of market based on share of TRxs for respective markets week ending 1/20, phentermine includes benzphetamine, diethylpropion and phendimetrazine Size = % share of market (tablet product
Slide 41: Review of 2016 and Preview of 2017
Review of 2016 and Preview of 2017 Strategy for Orexigen Re-Launch of Contrave Early Results for Orexigen Commercialization of Contrave Global Partnering Progress Post-Marketing Studies Early Program Development Summary
Slide 42: Global Obesity Rate Continues to Rise
2010 2000 472m 303m 2020 672m 2000 86m 2010 110m 2020 149m North America and Caribbean South and Central America Africa (AFR) Western Pacific SE Asia Europe Source: EuroMonitor, 2010; WHO Statistics Middle East and North Africa millions of people globally 2000 2020 2000 2010 2020 122m 144m 95m 2000
Slide 43: Increased Pace of OUS Deal Signings in 2016
Increased Pace of OUS Deal Signings in 2016 South Korea Central & Eastern Europe: Spain Canada Australia/ New Zealand South Africa 3Q 15 4Q 15 1Q 16 2Q 16 3Q 16 4Q 16 UK Ireland Middle East: Turkey Greece Poland Slovenia Slovakia Czech Hungary Croatia Lithuania Estonia Latvia Bulgaria Romania Serbia
Slide 44: Successfully Partnered a Significant Proportion of the OUS Opportunity
Signed partnerships with 5 companies spanning 38 countries that represent ~43% of OUS tier-1 obesity sales 2015 Obesity Rx Drug Sales1 in Tier-1 OUS markets Successfully Partnered a Significant Proportion of the OUS Opportunity Partnered Tier-1 Targets Region 2015 Sales ($M) Korea 66.7 Australia/New
Slide 45: Key Launches and Regulatory Submissions
Key Launches and Regulatory Submissions Submissions Launches 4Q 17 3Q 17 2Q 17 1Q 17 4Q 16 3Q 16 2Q 16 1Q 16 Saudi Arabia Lebanon UAE Kuwait Serbia South Africa Saudi Arabia Australia Canada Lebanon UAE Kuwait Greece Cyprus United Kingdom Ireland Spain Bulgaria Estonia Lithuania Latvia Croatia Slove
Slide 46: Review of 2016 and Preview of 2017
Review of 2016 and Preview of 2017 Strategy for Orexigen Re-Launch of Contrave Early Results for Orexigen Commercialization of Contrave Global Partnering Progress Post-Marketing Studies Early Program Development Summary
Slide 47: Post-Marketing Development Programs on Track
PMR 2017 2018 2019 2020 2021 2022 2024 DDI ◊ Juvenile Tox ◊ TQT ◊ Renal/Hepatic/Adolescent/Children PK ◊ x x x BE – Pediatric Formulation x Pediatric Phase III (Adolescents/Children) x x Drug Utilization x Observational Database x CVOT (Cardiovascular Outcomes Trial) x Post-Marketing Development Pro
Slide 48: Review of 2016 and Preview of 2017
Review of 2016 and Preview of 2017 Strategy for Orexigen Re-Launch of Contrave Early Results for Orexigen Commercialization of Contrave Global Partnering Progress Post-Marketing Studies Early Program Development Summary
Slide 49: Pre-Clinical Analgesic and Addiction-Management Programs
In 2015 Orexigen exclusively licensed two compound series from Bath University (UK) Extensive preclinical assessments have demonstrated meaningful therapeutic potential Moving both programs forward to key preclinical milestones in 2017 and exploring options for advancing to IND and into clinical tri
Slide 50: Addiction Management: Public Health Epidemics Beyond Obesity
Sources: NEJM 2016;374:154-63; CDC Wonder Addiction Management: Public Health Epidemics Beyond Obesity In 2014 there were 18.9k deaths from prescription-opioid overdose and 10.6k deaths from heroin overdose Opioid addiction is recognized as an urgent public health epidemic in the US Medication-assis
Slide 51: Medication-Assisted Treatment of Drug Addiction
Medication-Assisted Treatment of Drug Addiction Target Product Profile: opioid and possible cocaine addiction treatment, with clinical efficacy on par with buprenorphine and an improved tolerability and abuse-liability profile NCE: Orvinol/Thevinol derivative with lower activity at the Mu opioid rec
Slide 52: Pain Management: Opioids Continue To Be Standard of Care
Sources: North America Opioid Market, Grand View Research Nahin, Richard L, Estimates of Pain Prevalence and Severity in Adults: United States, 2012 The Journal of Pain, Vol 16 No 8, August 2015 Pain Management: Opioids Continue To Be the Standard of Care for Chronic Pain Management
Slide 53: Treatment of Chronic Moderate-to-Severe Pain Without Abuse Potential
Treatment of Chronic Moderate-to-Severe Pain Without Abuse Potential Target Product Profile: outpatient management of acute and chronic moderate to severe pain, without the abuse potential of current standard-of-care opioids NCE: Naltrexone analogue with partial agonist activity at Mu opioid and Noc
Slide 54: Review of 2016 and Preview of 2017
Review of 2016 and Preview of 2017 Strategy for Orexigen Re-Launch of Contrave Early Results for Orexigen Commercialization of Contrave Global Partnering Progress Post-Marketing Studies Early Program Development Summary
Slide 55: 2017 A Value Inflection Year
Drive Contrave growth in the US Implement an innovative, patient-focused education and awareness campaign Integrate physician programs with patient programs to drive higher quality discussions on Rx-assisted weight loss Realize significant OUS opportunity Support successful launches and approvals in
Slide 56: Orexigen
www.contrave.com is OREXIGEN
Orexigen Therapeutics — Corporate Update (March 2017) on 6ix